Close

content

spot_img

AbbVie Announces Positive Phase 3 Data for Atogepant in Migraine Prevention

AbbVie announced that the Phase 3 ADVANCE trial evaluating the investigational medicine atogepant, an orally administered calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) met...

FDA Grants Emergency Use Authorization for Eli Lilly, Sandia National Labs Coronavirus PCR Tests

The US FDA granted separate Emergency Use Authorizations for PCR-based SARS-CoV-2 tests developed by Eli Lilly and Sandia National Laboratories. The Lilly SARS-CoV-2 Assay is...

European Union signs Remdesivir deal with Gilead

The European Union's executive said that it has signed a contract with Gilead for its COVID-19 medicine remdesivir that would cover 30,000 patients in...

Sanofi and GSK agree with the UK government to supply up to 60 million doses of COVID-19 vaccine

Sanofi and GSK have reached an agreement, subject to final contract, with the UK government for the supply of up to 60 million doses...

Pfizer and BioNTech Choose Lead mRNA Vaccine Candidate Against COVID-19 and Pivotal Phase Global Study

Pfizer Inc. and BioNTech SE announced the start of a global (except for China) Phase 2/3 safety and efficacy clinical study to evaluate a single...

AstraZeneca’s Calquence Receives Positive CHMP Opinion For Chronic Blood Cancer

AstraZeneca’s Calquence has been recommended for marketing authorisation in the EU for the treatment of adult patients with chronic lymphocytic leukaemia (CLL), the most...

Catalent Enters into Strategic Partnership with Editas Medicine to Support Gene Editing Medicine Pipeline

Editas Medicine, Inc., a leading genome editing company, and Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs,...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Must read

spot_img